Author of

• 25967

  +

  P3.13 - Targeted Therapy (Not CME Accredited Session) (ID 979)

  • Event: WCLC 2018
  • Type: Poster Viewing in the Exhibit Hall
  • Track:
  • Presentations: 1
  • Moderators:
  • Coordinates: 9/26/2018, 12:00 - 13:30, Exhibit Hall

  • 27696

    +

    P3.13-30 - Driver Mutation in Heavy Smoker Patient with Squamous Cell Carcinoma Metastatic Lung Cancer: Case Report (ID 13546)

    12:00 - 13:30  |  Author(s): Ana Cecilia Barbalho De Vasconcelos
    • Abstract
    • Slides

    Background
    

    Nowadays, guidelines recommend to assess the presence of a driver mutation in tumors that contains an element of adenocarcinoma regardless of the clinical characteristics of the patient or squamous cell carcinoma in a patient that never smoked.

    a9ded1e5ce5d75814730bb4caaf49419 Method
    

    We reported a clinical case of a pacient that had a squamous cell carcinoma with a driver mutation in EGFR, despite the fact that he was a heavy smoker. the case occured in our service in the northeast of Brazil.

    4c3880bb027f159e801041b1021e88e8 Result
    

    Woman, 63 years old, current smoking, presented in a public health service in Brazil with history of cought and dyspneia 3 months earlier. In the investigation, CTS showed mass hilar in the right lung and enlarged lymphonodes in the mediastinum IPSI and contralateral, but there was no evidence of secondary lesios in other organs. She was submitted to a core biopsy CT guided that confirmed squamous cell carcinoma. The planned treatment was radiotherapy and concomitant chemotherapy. As in our service the time to start the radiotheraphy is about 3 months, we started a platin based chemotherapy and made sequencial radiotherapy. After that, she was submitted to new CTS that showed partial response in the lung and lymphnodes, but there was evidence of bone metastatis in the sacrum and left iliac. In our service, there was a trial in which all patients diagnosed with lung cancer had it’s tissue avaliated for driver mutation, and we received the results with a driver mutation in exon 19 of EGFR. So, we started a treatment with Erlotinib with a great response and, now, after 9 months, it’s still responding.

    8eea62084ca7e541d918e823422bd82e Conclusion
    

    This case represent a rare case of a squamous cell carcinoma with a driver mutation in a current smoking, and maybe justified by the fact that the tumor had an adenosquamous component. If the patient wasn’t tested for driver mutations, she would never received an target therapy. Thus, maybe we should assessed all non small lung cancers for the driver mutations.

    6f8b794f3246b0c1e1780bb4d4d5dc53

    Only Active Members that have purchased this event or have registered via an access code will be able to view this content. To view this presentation, please login or select "Add to Cart" and proceed to checkout.